Owlet, a baby technology company, is expanding its Dream Sock baby monitor to several European countries, monitoring infants’ health readings like heart rate, oxygen saturation, and sleep state. The device received FDA clearance and CE Mark certification. Owlet’s CEO Kurt Workman expressed excitement at the technology’s impact on families. The company went public in 2021 and reported increased revenue in the second quarter of 2024. Despite a decrease in stock price, Owlet raised significant funding and expects continued growth, projecting full-year revenue of $72.5 million to $77.5 million with an adjusted EBITDA loss of $6 million to $3 million.
Source link
Infant monitoring company Owlet expands across Europe
